Skip to main content
. 2023 May 12;123(8):808–839. doi: 10.1055/a-2052-9175

Fig. 5.

Fig. 5

Biotransformation and metabolization of the oral P2Y12-inhibitors. Antithrombotic therapy can be personalized by (1) using CYP2C19 genotype-guided therapy, which is the only genetic polymorphism for which a genotype-guided therapy is assessed in randomized clinical trials or (2) assessing the actual responsiveness to antiplatelet therapy by measuring on-treatment platelet reactivity, which is influenced by different modifiable and nonmodifiable factors.